Literature DB >> 23816136

miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O.

Binghai Chen1, Lujing Duan, Guangming Yin, Jing Tan, Xianzhen Jiang.   

Abstract

BACKGROUND: Few researches on increase of chemotherapy sensitivity by microRNA (miRNA) were reported. We aim to investigate exact role of miR-381 in chemotherapy sensitivity of 5-fluorouracil (5-FU) in renal cancer cells.
METHODS: We investigated the cell survival, cell-cycle and apoptosis of 786-O and HK-2 cells treated with miR-381 and 5-FU. IC50 of 5-FU was calculated. To study apoptosis and G2/M arrest, we determined pHH3, mitotic index and caspase-3/7 activity.
RESULTS: We showed that miR-381 combined with 5-FU inhibited proliferation and potentiated the anti-tumour efficacies of 5-FU at tolerated concentration in vitro. miR-381 combined with 5-FU led to Cdc2 activation, mitotic catastrophe, and cell apoptosis through inhibitory WEE1. WEE1 was also validated as the direct target of miR-381. IC50 of 5-FU decreased significantly in the presence of miR-381.
CONCLUSION: miR-381 increases sensitivity of 786-O cells to 5-FU by inhibitory WEE1 and increase of Cdc2 activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23816136     DOI: 10.1179/1973947813Y.0000000092

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  23 in total

Review 1.  Genomic integrity and the ageing brain.

Authors:  Hei-man Chow; Karl Herrup
Journal:  Nat Rev Neurosci       Date:  2015-10-14       Impact factor: 34.870

2.  MicroRNA-381 suppresses proliferation and invasion of prostate cancer cells through downregulation of the androgen receptor.

Authors:  Xin Rui; Ting-Ting Gu; Hua-Feng Pan; Si-Liang Shao; Hong-Xiang Shao
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

3.  MicroRNA-381 increases radiosensitivity in esophageal squamous cell carcinoma.

Authors:  Suna Zhou; Wenguang Ye; Juan Ren; Qiuju Shao; Yuhong Qi; Jun Liang; Mingxin Zhang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  MiR-381 inhibits migration and invasion in human gastric carcinoma through downregulatedting SOX4.

Authors:  Mingming Zhang; Shishu Huang; Dan Long
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

5.  Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.

Authors:  Zeyou Wang; Jing Yang; Gang Xu; Wei Wang; Changhong Liu; Honghui Yang; Zhibin Yu; Qianqian Lei; Lan Xiao; Jing Xiong; Liang Zeng; Juanjuan Xiang; Jian Ma; Guiyuan Li; Minghua Wu
Journal:  Oncotarget       Date:  2015-02-20

Review 6.  MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).

Authors:  Ming Li; Ying Wang; Yongsheng Song; Renge Bu; Bo Yin; Xiang Fei; Qizhen Guo; Bin Wu
Journal:  Oncol Rep       Date:  2015-02-13       Impact factor: 3.906

7.  MicroRNA-381 Negatively Regulates TLR4 Signaling in A549 Cells in Response to LPS Stimulation.

Authors:  Zhihao Xu; Dapeng Dong; Xiaofei Chen; Huaqiong Huang; Shenglan Wen
Journal:  Biomed Res Int       Date:  2015-11-24       Impact factor: 3.411

8.  MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression.

Authors:  Qinghua Cao; Fang Liu; Kaiyuan Ji; Ni Liu; Yuan He; Wenhui Zhang; Liantang Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-02-13

9.  Identification and Characterization of MicroRNAs from Longitudinal Muscle and Respiratory Tree in Sea Cucumber (Apostichopus japonicus) Using High-Throughput Sequencing.

Authors:  Hongdi Wang; Shikai Liu; Jun Cui; Chengze Li; Yucai Hu; Wei Zhou; Yaqing Chang; Xuemei Qiu; Zhanjiang Liu; Xiuli Wang
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

10.  Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.

Authors:  Yunchao Li; Chunhua Zhao; Zhibin Yu; Jiarui Chen; Xiaoling She; Peiyao Li; Changhong Liu; Yan Zhang; Jianbo Feng; Haijuan Fu; Bing Wang; Lei Kuang; Lei Li; Guohua Lv; Minghua Wu
Journal:  Oncotarget       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.